228 related articles for article (PubMed ID: 24680381)
1. A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children.
Hansen KE; Kleker B; Safdar N; Bartels CM
Semin Arthritis Rheum; 2014 Aug; 44(1):47-54. PubMed ID: 24680381
[TBL] [Abstract][Full Text] [Related]
2. Osteoporotic Fractures and Vertebral Body Reshaping in Children With Glucocorticoid-treated Rheumatic Disorders.
Ward LM; Ma J; Robinson ME; Scharke M; Ho J; Houghton K; Huber A; Scuccimarri R; Barsalou J; Roth J; Shenouda N; Matzinger MA; Lentle B; Jaremko JL; Koujok K; Watanabe Duffy K; Stein R; Sbrocchi AM; Rodd C; Miettunen PM; LeBlanc CMA; Larche M; Jurencak R; Cummings EA; Couch R; Cabral DA; Atkinson S; Alos N; Sykes E; Konji VN; Rauch F; Siminoski K; Lang B
J Clin Endocrinol Metab; 2021 Nov; 106(12):e5195-e5207. PubMed ID: 34232311
[TBL] [Abstract][Full Text] [Related]
3. Effects of glucocorticoids on osteoporosis in rheumatoid arthritis: a systematic review and meta-analysis.
Wang Y; Zhao R; Gu Z; Dong C; Guo G; Li L
Osteoporos Int; 2020 Aug; 31(8):1401-1409. PubMed ID: 32291467
[TBL] [Abstract][Full Text] [Related]
4. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
[TBL] [Abstract][Full Text] [Related]
5. Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic Disorders.
LeBlanc CM; Ma J; Taljaard M; Roth J; Scuccimarri R; Miettunen P; Lang B; Huber AM; Houghton K; Jaremko JL; Ho J; Shenouda N; Matzinger MA; Lentle B; Stein R; Sbrocchi AM; Oen K; Rodd C; Jurencak R; Cummings EA; Couch R; Cabral DA; Atkinson S; Alos N; Rauch F; Siminoski K; Ward LM;
J Bone Miner Res; 2015 Sep; 30(9):1667-75. PubMed ID: 25801315
[TBL] [Abstract][Full Text] [Related]
6. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis.
Kaji H; Yamauchi M; Chihara K; Sugimoto T
Endocr J; 2006 Feb; 53(1):27-34. PubMed ID: 16543669
[TBL] [Abstract][Full Text] [Related]
7. Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome.
Phan V; Blydt-Hansen T; Feber J; Alos N; Arora S; Atkinson S; Bell L; Clarson C; Couch R; Cummings EA; Filler G; Grant RM; Grimmer J; Hebert D; Lentle B; Ma J; Matzinger M; Midgley J; Pinsk M; Rodd C; Shenouda N; Stein R; Stephure D; Taback S; Williams K; Rauch F; Siminoski K; Ward LM;
Osteoporos Int; 2014 Feb; 25(2):627-37. PubMed ID: 23948876
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis.
Mori Y; Izumiyama T; Baba K; Mori N; Fujii H; Ishii T; Itoi E
J Orthop Surg Res; 2020 Jul; 15(1):290. PubMed ID: 32727595
[TBL] [Abstract][Full Text] [Related]
9. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
[TBL] [Abstract][Full Text] [Related]
10. Quantitative computed tomography of the lumbar spine, not dual x-ray absorptiometry, is an independent predictor of prevalent vertebral fractures in postmenopausal women with osteopenia receiving long-term glucocorticoid and hormone-replacement therapy.
Rehman Q; Lang T; Modin G; Lane NE
Arthritis Rheum; 2002 May; 46(5):1292-7. PubMed ID: 12115236
[TBL] [Abstract][Full Text] [Related]
11. Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome.
Feber J; Gaboury I; Ni A; Alos N; Arora S; Bell L; Blydt-Hansen T; Clarson C; Filler G; Hay J; Hebert D; Lentle B; Matzinger M; Midgley J; Moher D; Pinsk M; Rauch F; Rodd C; Shenouda N; Siminoski K; Ward LM;
Osteoporos Int; 2012 Feb; 23(2):751-60. PubMed ID: 21494860
[TBL] [Abstract][Full Text] [Related]
12. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
13. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases.
Kumagai S; Kawano S; Atsumi T; Inokuma S; Okada Y; Kanai Y; Kaburaki J; Kameda H; Suwa A; Hagiyama H; Hirohata S; Makino H; Hashimoto H
J Rheumatol; 2005 May; 32(5):863-9. PubMed ID: 15868623
[TBL] [Abstract][Full Text] [Related]
14. Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders.
Huber AM; Gaboury I; Cabral DA; Lang B; Ni A; Stephure D; Taback S; Dent P; Ellsworth J; LeBlanc C; Saint-Cyr C; Scuccimarri R; Hay J; Lentle B; Matzinger M; Shenouda N; Moher D; Rauch F; Siminoski K; Ward LM;
Arthritis Care Res (Hoboken); 2010 Apr; 62(4):516-26. PubMed ID: 20391507
[TBL] [Abstract][Full Text] [Related]
15. Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases: A meta-analysis.
Kan SL; Yuan ZF; Li Y; Ai J; Xu H; Sun JC; Feng SQ
Medicine (Baltimore); 2016 Jun; 95(25):e3990. PubMed ID: 27336902
[TBL] [Abstract][Full Text] [Related]
16. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.
Yanbeiy ZA; Hansen KE
Drug Des Devel Ther; 2019; 13():2843-2852. PubMed ID: 31616133
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid-induced osteoporosis: is the bone density decrease the only explanation?
Lespessailles E; Poupon S; Adriambelosoa N; Pothuaud L; Siroux V; Bouillon S; Benhamou CL
Joint Bone Spine; 2000; 67(2):119-26. PubMed ID: 10769104
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials.
Liu Z; Zhang M; Shen Z; Ke J; Zhang D; Yin F
PLoS One; 2020; 15(12):e0243851. PubMed ID: 33326444
[TBL] [Abstract][Full Text] [Related]
19. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study.
Majumdar SR; Morin SN; Lix LM; Leslie WD
Osteoporos Int; 2013 Sep; 24(9):2493-8. PubMed ID: 23572142
[TBL] [Abstract][Full Text] [Related]
20. Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study.
Inoue Y; Mitsunaga K; Yamamoto T; Chiba K; Yamaide F; Nakano T; Morita Y; Yamaide A; Suzuki S; Arima T; Yamaguchi KI; Tomiita M; Shimojo N; Kohno Y
Pediatr Rheumatol Online J; 2018 Jun; 16(1):36. PubMed ID: 29914510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
